Rani Therapeutics Holdings, Inc. (RANI) — SEC Filings
Rani Therapeutics Holdings, Inc. (RANI) — 30 SEC filings. Latest: S-8 (Mar 26, 2026). Includes 16 8-K, 6 10-Q, 2 DEF 14A.
View Rani Therapeutics Holdings, Inc. on SEC EDGAR
Overview
Rani Therapeutics Holdings, Inc. (RANI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-8 filed on Mar 26, 2026: Rani Therapeutics Holdings, Inc. filed an S-8 form on March 26, 2026, to register securities for its employee benefit plans. This filing allows the company to offer stock options or other equity-based compensation to its employees. The filing does not involve a specific dollar amount but pertains to
Sentiment Summary
Across 30 filings, the sentiment breakdown is: 4 bearish, 26 neutral. The dominant filing sentiment for Rani Therapeutics Holdings, Inc. is neutral.
Filing Type Overview
Rani Therapeutics Holdings, Inc. (RANI) has filed 1 S-8, 6 10-Q, 16 8-K, 1 DEFA14A, 2 DEF 14A, 2 10-K, 1 SC 13G, 1 SC 13D/A with the SEC between Feb 2024 to Mar 2026.
Filings by Year
Recent SEC Filings (30)
Risk Profile
Risk Assessment: Of RANI's 26 recent filings, 4 were flagged as high-risk, 10 as medium-risk, and 12 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Net Income | -$7.914M |
| Cash Position | $4.144M |
| Total Assets | $10.139M |
| Total Debt | $0.00 |
Key Executives
- Dr. David S. Leo
- Luis Felipe Correa González
Industry Context
Rani Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on developing novel drug delivery systems. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Companies in this space often rely on substantial external funding to advance their pipelines through clinical trials and towards commercialization.
Top Tags
financials (4) · 10-Q (4) · material-agreement (3) · corporate-governance (3) · sec-filing (2) · Biotechnology (2) · Pharmaceuticals (2) · Cash Burn (2) · Net Loss (2) · governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $7.914M | 37.8% improvement from $12.722M in Q3 2024 |
| Net Loss (9M 2025) | $31.876M | 21.9% reduction from $40.862M in 9M 2024 |
| Cash and Cash Equivalents | $4.144M | Increased from $3.762M at Dec 31, 2024 |
| Total Assets | $10.139M | Decreased from $36.634M at Dec 31, 2024 |
| Research and Development Expenses (Q3 2025) | $3.221M | 47.8% decrease from $6.172M in Q3 2024 |
| General and Administrative Expenses (Q3 2025) | $4.036M | 28.3% decrease from $5.627M in Q3 2024 |
| Debt Repayment (9M 2025) | $11.250M | Reduced long-term debt to zero |
| Total Stockholders' Deficit | $11.973M | Worsened from $3.493M equity at Dec 31, 2024 |
| Proceeds from July 2025 Securities Purchase Agreement | $2.811M | Capital raised from common stock and pre-funded warrants |
| Net Cash Used in Operating Activities (9M 2025) | $19.008M | Indicates ongoing cash burn |
| Revenue | $0 | No revenue reported for Q2 2025 or YTD 2025, indicating pre-commercial stage. |
| Net Loss (Q2 2025) | -$20.5M | Represents a slight improvement from -$22.1M in Q2 2024. |
| Net Loss (YTD 2025) | -$41.0M | Represents a slight improvement from -$44.5M in YTD 2024. |
| R&D Expenses (Q2 2025) | $15.0M | Decreased from $16.5M in Q2 2024, showing controlled spending. |
| R&D Expenses (YTD 2025) | $30.0M | Decreased from $33.0M in YTD 2024, reflecting ongoing development costs. |
Frequently Asked Questions
What are the latest SEC filings for Rani Therapeutics Holdings, Inc. (RANI)?
Rani Therapeutics Holdings, Inc. has 30 recent SEC filings from Feb 2024 to Mar 2026, including 16 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RANI filings?
Across 30 filings, the sentiment breakdown is: 4 bearish, 26 neutral. The dominant sentiment is neutral.
Where can I find Rani Therapeutics Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Rani Therapeutics Holdings, Inc. (RANI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Rani Therapeutics Holdings, Inc.?
Key financial highlights from Rani Therapeutics Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for RANI?
The investment thesis for RANI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Rani Therapeutics Holdings, Inc.?
Key executives identified across Rani Therapeutics Holdings, Inc.'s filings include Dr. David S. Leo, Luis Felipe Correa González.
What are the main risk factors for Rani Therapeutics Holdings, Inc. stock?
Of RANI's 26 assessed filings, 4 were flagged high-risk, 10 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Rani Therapeutics Holdings, Inc.?
Forward guidance and predictions for Rani Therapeutics Holdings, Inc. are extracted from SEC filings as they are enriched.